구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Blinatumomab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel mechanisms of action that traditional monoclonal antibodies cannot achieve |
Positioning Known limitation | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
MoA Mechanism | targeting CD19/20/22 and engineered chimeric antigen receptor |
MoA Biomarker | CD19 expression, whereas cytoplasmic CD22 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Toxicology CRS | 1% |
Clinical Safety signal | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Clinical Selected reported efficacy | 10% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03298412 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03298412 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Blinatumomab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel mechanisms of action that traditional monoclonal antibodies cannot achieve |
Positioning Known limitation | bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model |
MoA Mechanism | targeting CD19/20/22 and engineered chimeric antigen receptor |
MoA Biomarker | CD19 expression, whereas cytoplasmic CD22 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Toxicology CRS | 1% |
Clinical Safety signal | Blinatumomab administration in the outpatient setting: Safety and health care utilization.. Blinatumomab, a bispecific CD19 × CD3 antibody is effective for the treatment of B-cell acute lymphoblastic leukemia (ALL). Because of its immune toxicities, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the US Food and Drug Administration (F… |
Clinical Selected reported efficacy | 10% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03298412 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03298412 |
추천 비교
추천 비교